New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.50 1.76 +1.33%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Merck & Co., Inc. 10-Q filed Aug 5, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed · accepted 4:13 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 2, 2025: 22 added · 5 removed · 65 modified; 3 with only figures updated

  1. Added · Business Development Transactions

    In July 2025, Merck entered into a definitive agreement to acquire Verona Pharma plc (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, for $107 per American Depository Share (each of which represents eight Verona Pharma ordinary shares) for a total transaction value of approximately $10 billion. Through this acquisition, Merck will acquire Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterases 3 and 4 (PDE3 and PDE4), which was approved in the U.S. in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients and is also being evaluated in clinical trials for the treatment of non-cystic fibrosis bronchiectasis. Closing of the acquisition is expected in the fourth quarter of 2025, but is subject to certain conditions, including approval under the Hart-Scott-Rodino Antitrust Improvements Act, approval of Verona Pharma’s shareholders, sanction by the High Court of Justice of England and Wales and other customary conditions. If the proposed transaction closes, the Company expects to capitalize most of the purchase price as an intangible asset for Ohtuvayre.